In conclusion, we have carried out a transcriptome-wide expression profile in nine paired benign and malignant PCa samples and constructed a novel five-gene-based prognostic model (PCBP1, PABPN1, PTPRF, DANCR, and MYC) that is capable of classifying PCa patients into high- and low-risk groups with respect to PFS. This evidence concerns the gene MYC and posterior cortical atrophy.